Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Trevor Williams In the tale of two large-cap pharma stocks it was a contrast in expectations, and performance on Tuesday morning, July 30 ’24, as Pfizer (NYSE:PFE, NEOE:PFE:CA) , with very low expectations coming into the release, but technically improved in the last month, sharply contrasted with Merck, which disappointed coming into the release, after seeing good growth around Keytruda, and Gardasil in prior quarters. As of last Friday, July 26th ’24, Merck was +16.31% YTD as of Friday night’s close,  ...